Phase I Study to Evaluate the Safety and Pharmacokinetics of JP-1366 in Healthy Adult Volunteers
Abstract
To evaluate the safety and the pharmacokinetics of the JP-1366 20 mg tablet and capsule oral administration in healthy adult volunteers.
Conditions: Healthy.
Primary outcome: AUCt of Zastaprazan(JP-1366 20mg); Cmax of Zastaprazan(JP-1366 20mg).
Enrollment: 30 participants.
How strong is the evidence?
Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 30 participants or records.
Read the paper
Related studies
- The impact of the COVID-19 epidemic on mental health of undergraduate students in New Jersey, cross-sectional study
- Household Secondary Attack Rate of COVID-19 and Associated Determinants in Guangzhou, China: A Retrospective Cohort Study
- Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study
- Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study
- Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study
- Population-based rates, timing, and causes of maternal deaths, stillbirths, and neonatal deaths in south Asia and sub-Saharan Africa: a multi-country prospective cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.